Gemalon™ 500 (60)
Gemalon™ 500 provides immediate support for the body’s defense without the stimulation of the immune system. Highly bioavailable, fast absorbing, instantized bovine serum protein concentrate with optimal concentration of IgG.
DOES NOT CONTAIN antibiotics and hormones, saturated fat, lactose, and casein.
The product has been manufactured using high quality pure raw materials and the technology that ensures all their beneficial properties intact, in strict compliance with GMP and TÜV regulations.
· helps support and strengthen the immune system
· supports intestinal health
· inhibits the growth of pathogenic bacteria
Stress, unbalanced diet, medication, excess physical activity, and growing older – all these factors weaken the immune system. The control and treatment of infectious diseases is increasingly complicated by the development of antibiotic-resistant organisms, and the emergence and rapid dissemination of new pathogens. As most pathogens enter through mucosal surfaces, the local immune defence may be of particular importance. (1)
Effective defense of the body highly depends on the amount of immunoglobulins - molecules that are produced by plasma cells in response to an antigen. An antigen is any foreign substance that enters the body, usually by ingestion, inhalation, or breaks in the skin and causes an immune response. Antibodies are specific to a given antigen.
Immunoglobulin is a protein used by the immune system to identify and neutralize foreign objects.
Immunoglobulins are so important for the defense of the human body, that their concentration is considered the primary index of immune system health.
The basic functions of immunoglobulins are the neutralization and opsonization of bacteria, viruses, and other environmental pathogens.
Neutralization means that the antibodies have bound to an antigen and this prevents the antigen from finding its target. For example, if the antigen bund by an antibody is a protein comprising part of a bacterium or virus, the antibody can prevent the attachment of the bacteria or virus to the host. Likewise, binding of an antibody to a toxin prevents the uptake of the toxin by the body. In both examples, the antibody has effectively neutralized the bacteria, virus and/or toxin.
Opsonization describes the coating of an antigen with antibodies so that it can be recognized as foreign; ingested by specialized white blood cells; destroyed; and, presented on the surface of the white blood cells for recognition by the other cells of the immune system. Unlike antibiotics, antibodies also allow the immune system to specifically recognize pathogens while ignoring good bacteria that are a part of the body’s normal microflora.
Gemalon™ 500 is a unique Santegra®’s product - highly bioavailable bovine serum protein concentrate rich in peptides and immunoglobulins. It’s an all-natural and lactose-free.
Bovine serum protein concentrate is derived from cattle specifically raised for food. Such food animals produce specific humoral immunity against a broad range of organisms because they are routinely exposed to common environmental pathogens to a much greater degree than humans.
As a result, immunoglobulin of bovine origin contains antibodies that are also specific to human pathogens. This includes such pathogens as E. coli, H. pylori, and rotavirus.
Bovine serum protein concentrate is prepared from BSE free bovine source material, collected under rigid USDA inspection, and manufactured in a FDA compliant, GMP plant.
The patent pending cold manufacturing process positions the fast absorbing instantized bovine serum protein concentrate as the next evolution and will change the way you think of proteins.
The key bioactive component of serum concentrate, immunoglobulin, is also found in bovine milk and colostrum (the milk-like liquid produced by the cow for the first few hours after giving birth). But, because it is processed from bovine blood, rather than the milk, it contains no lactose and almost no fat due to the fractioning process. The serum also contains no allergenic proteins, such as the beta-lactoglobulin that is found in colostrum.
Gemalon™ 500 contains 500 – 750 mg IgG in the daily dosage.
Gemalon™ 500 does not contain antibiotics and synthetic hormones.
Gemalon™ 500 is a high quality, bioactive protein supplement that provides high levels of IgG.
The characteristic that sets Gemalon™ 500 apart from other immune support products is its immediate effect. Many popular immune support ingredients may take weeks to promote immune function. Gemalon™ 500 works as soon as it becomes soluble.
In the modern world with the increase in number of pathogens, the immune system support with all natural and safe product Gemalon™ 500 could be very beneficial to long-term human health.
Per 4 tablets:
immunoglobulin IgG – 250 mg.
60 chewable tablets.
as a dietary supplement, take four tablets two to three times a day.
decreased immune response, conditions after surgery and illnesses, intestinal microflora imbalance, prevention of infectious diseases.
How we get sick, feel achy and run down…
Our body’s immune system defends against infection and illness by releasing immunoglobulin (antibodies.)
Many germs enter our bodies through ingestion. They end up in the 400 sq. feet of GI tract surface area where immunoglobulin works to neutralize the germs.
But, our immune system, weakened from busy lives, stress, aging and crowded conditions doesn’t have the resources to fight germs at point of entry.
The body, now under distress, actually releases less immunoglobulin to the GI tract as it prepares to use its resources elsewhere.
Fewer antibodies decrease our ability to fight and increase our susceptibility to illness.
The germs activate the immune system and trigger inflammatory cytokine production (IL-1, IL-6 and TNF-a.) Cytokines break down body protein into amino acids. The liver processes the amino acids and they are lost as urea until metabolism comes back to normal. We feel achy and run down.
We feel bad for 5 to 7 days, or until the body can produce enough specific antibodies to fight the germs.
Why Oral Supplementation?
The transfer of immunity through oral supplementation is a natural, logical and effective process for obtaining immunity. First, immunoglobulin is the principal anti-infective component of breast-milk and colostrum. In adults, the concentration of immunoglobulin in the digestive tract
and on mucosal surfaces is predictive of the risk of infection.
Stress and many other conditions increase the risk of infection by reducing immunoglobulin secretion and antibody production. (2) Oral immunoglobulin supplementation has been found to help preserve the normal protective barrier of the digestive tract and provide humoral immunity to the gut.
Oral supplementation of Gemalon™ 500 provides immediate support to the immune system.
The all-natural immunoglobulin in Gemalon™ 500 goes to work immediately to neutralize germs. Inflammatory cytokine production is reduced. We feel better within hours! And with continued supplementation, we stay healthy day after day!
The Gut Connection to Good Health
Almost 80% of all disease and infections enter the body either through mucosal tissue or stay localized on mucosal surfaces. Immune cells located in the digestive tract produce tremendous quantities, approximately 5 g per day, of immunoglobulin in the form of secretory IgA, which prevents and resolves infections from any pathogenic organisms (bacteria, viruses and others) and toxins normally found in the gut.
Supplemental immunoglobulins first act in the intestinal tract to eliminate or inhibit the proliferation of disease-causing organisms and toxins. It is this action against invading antigens in the bowel that creates the link between the gut and the rest of the body. The inhibition of the growth of opportunistic organisms or the absorption of toxins by the bowel reduces the stimulation of the immune system. Thus, the body’s resources, particularly amino acids, which would normally be directed towards those challenges, can be redirected to other "battles" in other parts of the body.
Supplementation with immunoglobulins reduces the demand in the gut for naturally produced antibodies. Since the body’s resources are finite, conservation of immune resources in the gut allows more resources to be available wherever else they may be needed.
One of the primary studies on bovine serum as a source of immunoglobulin was conducted on recovering malnourished children. The researchers reported that bovine serum was well tolerated and resulted in improved energy retention with supplementation at a dose of 8 and 16 g bovine serum concentrate for 7 days. (3)
Consumption of bovine serum immunoglobulin appears to positively modulate the primary lipid indexes associated with cardiovascular disease. (4)
Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy.
All eight participants experienced profound improvement in symptoms with reduced bowel movements/day (P = 0.008) and improvements in stool consistency (P = 0.008). Gut permeability was normal before and after the intervention, but D-xylose absorption increased in seven of eight participants. Mucosal CD4 lymphocyte densities increased by a median of 139.5 cells/mm2 from 213 to 322 cells/mm2 (P = 0.016). Intestinal-fatty acid binding protein (I-FABP), a marker of enterocyte damage, initially rose in seven of eight participants after 8 weeks (P = 0.039), and then fell below baseline in four of five who continued receiving SBI (P = 0.12). Baseline serum I-FABP levels were negatively correlated with subsequent rise in mucosal CD4 lymphocyte densities (r = -0.74, P = 0.046).
SBI significantly increases intestinal mucosal CD4 lymphocyte counts, improves duodenal function, and showed evidence of promoting intestinal repair in the setting of HIV enteropathy. (5)
Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome.
Subjects who received SBI at 10 g/day (N = 15) had statistically significant within-group reductions in abdominal pain (p < 0.01), loose stools (p < 0.01), bloating (p < 0.05), flatulence (p < 0.01), urgency (p < 0.05) and any symptom (p < 0.01) at EOT vs. baseline. Subjects receiving 5 g/day of SBI (N = 15) realized statistically significant within-group reductions in days with flatulence (p < 0.035), incomplete evacuation (p < 0.05), and any symptom (p < 0.01). There were no significant changes in QoL scores or in hematology or clinical chemistry among treatment groups.
This pilot study showed that nutritional therapy with either 10 g/day or 5 g/day of SBI in 30 patients was well tolerated and resulted in statistically significant within group improvements in both symptom days and in daily symptom scores in subjects with IBS-D. Additional studies are underway with larger numbers of subjects to validate these findings. (6)
Serum-derived bovine immunoglobulin/protein isolate: postulated mechanism of action for management of enteropathy.
The health and performance of the gastrointestinal tract is influenced by the interaction of a variety of factors, including diet, nutritional status, genetics, environment, stress, the intestinal microbiota, immune status, and gut barrier. Disruptions in one or more of these factors can lead to enteropathy or intestinal disorders that are known to occur in concert with certain disease states or conditions such as irritable bowel syndrome or human immunodeficiency virus (HIV) infection. Nutritional support in the form of a medical food along with current therapies could help manage the adverse effects of enteropathy, which include effects on nutrient digestion, absorption, and metabolism, as well as utilization of nutrients from foodstuffs. Numerous studies have demonstrated that oral administration of plasma- or serum-derived protein concentrates containing high levels of immunoglobulins can improve weight management, normalize gut barrier function, and reduce the severity of enteropathy in animals. Recent trials in humans provide preliminary evidence that a serum-derived bovine immunoglobulin/protein isolate is safe and improves symptoms, nutritional status, and various biomarkers associated with enteropathy in patients with HIV infection or diarrhea-predominant irritable bowel syndrome. This review summarizes data from preclinical and clinical studies with immunoglobulin-containing plasma/serum protein concentrates, with a focus on the postulated mode of action of serum-derived bovine immunoglobulin/protein isolate for patients with enteropathy. (7)
1. Weiner C1, Pan Q, Hurtig M, Borén T, Bostwick E, Hammarström L. Passive immunity against human pathogens using bovine antibodies. Clin Exp Immunol. 1999 May;116(2):193-205.
2. Jemmatt JB, et al. Academic stress, power motivation, and decrease in secretion rate of salivary secretory immunoglobulin A. Lancer 1983 Jun 25; I (8339): 1400-2.
3. Lembcke JL1, Peerson JM, Brown KH. Acceptability, safety, and digestibility of spray-dried bovine serum added to diets of recovering malnourished children. J Pediatr Gastroenterol Nutr. 1997 Oct;25(4):381-4.
4. Conrad P. Earnest, Alexander Jordan, and Eric Weaver. Cholesterol-lowering effects of bovine serum immunoglobulin in participants with mild hypercholesterolemia. 9/10/2004
5. Asmuth DM1, Ma ZM, Albanese A, Sandler NG, Devaraj S, Knight TH, Flynn NM, Yotter T, Garcia JC, Tsuchida E, Wu TT, Douek DC, Miller CJ. Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. AIDS. 2013 Sep 10;27(14):2207-17. doi: 10.1097/QAD.0b013e328362e54c.
6. Wilson D1, Evans M2, Weaver E3, Shaw AL3, Klein GL3. Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin Med Insights Gastroenterol. 2013 Dec 5;6:49-60. doi: 10.4137/CGast.S13200. eCollection 2013.
7. Petschow BW1, Burnett B1, Shaw AL1, Weaver EM1, Klein GL1.Serum-derived bovine immunoglobulin/protein isolate: postulated mechanism of action for management of enteropathy. Clin Exp Gastroenterol. 2014 May 24;7:181-90. doi: 10.2147/CEG.S62823. eCollection 2014.